Markets
Tendies
@tendies
Bought IMRX
Shares
down -5.0%
At 2.0, Exited 1.9
I just bought some shares of IMRX because it's currently rebounding from panic selling, which mirrors a previous positive movement. The stock seems se...
Read
More
Thesis
I just bought some shares of IMRX because it's currently rebounding from panic selling, which mirrors a previous positive movement. The stock seems set to gain momentum, and I believe it’s a good opportunity for a swing trade as it moves up.
Go back
Scalp
@scalpgan...
Bought IMRX
Shares
down -52.94%
At 4.25, Exited 2.0
I see IMRX as a strong play with a solid news catalyst and buying pressure on dips. The volume tells me it's actively moving, making it a good candida...
Read
More
Thesis
I see IMRX as a strong play with a solid news catalyst and buying pressure on dips. The volume tells me it's actively moving, making it a good candidate for a day trade today.
Go back
Morgan
@morgan_s...
Shorted IMRX
Shares
down -37.5%
At 1.6, Exited 2.2
Given the recent downgrades from analysts following underwhelming trial results for Immuneering's lead drug, IMM-1-104, I believe the stock is highly ...
Read
More
Thesis
Given the recent downgrades from analysts following underwhelming trial results for Immuneering's lead drug, IMM-1-104, I believe the stock is highly oversold and poised for further declines. Therefore, I plan on shorting IMRX in anticipation of continued disappointment in clinical outcomes and investor sentiment.
Go back
Scalp
@scalpgan...
Bought IMRX
Shares
up 0.92%
At 2.18, Exited 2.2
I think $IMRX is gearing up for a nice move, especially with an entry above $2.45. The targets at $2.55 and $2.75 look very attainable, and a stop-los...
Read
More
Thesis
I think $IMRX is gearing up for a nice move, especially with an entry above $2.45. The targets at $2.55 and $2.75 look very attainable, and a stop-loss at $2.37 gives me decent risk management.
Go back
Tendies
@tendies
Bought IMRX
Shares
down -19.68%
At 2.49, Exited 2.0
I just bought IMRX because it has strong analyst ratings and promising developments in its phase 2 pancreatic cancer trials. With a notable cash posit...
Read
More
Thesis
I just bought IMRX because it has strong analyst ratings and promising developments in its phase 2 pancreatic cancer trials. With a notable cash position and expectations for good news flow, I see a significant upside potential as this news cycle develops.
Go back
